Merck: Keytruda indication expanded in China
(CercleFinance.com) - Merck announces that its Keytruda treatment has been approved by the Chinese authorities in combination with platinum-based chemotherapy for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC).
Based on the results of a Phase III trial, this combination improves overall survival by reducing the risk of death by 28% compared with placebo plus chemotherapy.
It also reduces the risk of recurrence, progression or death by 42%.
Keytruda already has several indications for NSCLC in China, and this new authorization targets the unmet needs of patients at an earlier stage.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Based on the results of a Phase III trial, this combination improves overall survival by reducing the risk of death by 28% compared with placebo plus chemotherapy.
It also reduces the risk of recurrence, progression or death by 42%.
Keytruda already has several indications for NSCLC in China, and this new authorization targets the unmet needs of patients at an earlier stage.
Copyright (c) 2024 CercleFinance.com. All rights reserved.